摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-{(2R,3R,4S,5S)-5-[(S)-1-((2S,3R,4S,5R)-5-Azidomethyl-3,4-dihydroxy-tetrahydro-furan-2-yloxy)-2-hydroxy-ethyl]-3,4-dihydroxy-tetrahydro-furan-2-yl}-1H-pyrimidine-2,4-dione | 302917-36-8

中文名称
——
中文别名
——
英文名称
1-{(2R,3R,4S,5S)-5-[(S)-1-((2S,3R,4S,5R)-5-Azidomethyl-3,4-dihydroxy-tetrahydro-furan-2-yloxy)-2-hydroxy-ethyl]-3,4-dihydroxy-tetrahydro-furan-2-yl}-1H-pyrimidine-2,4-dione
英文别名
——
1-{(2R,3R,4S,5S)-5-[(S)-1-((2S,3R,4S,5R)-5-Azidomethyl-3,4-dihydroxy-tetrahydro-furan-2-yloxy)-2-hydroxy-ethyl]-3,4-dihydroxy-tetrahydro-furan-2-yl}-1H-pyrimidine-2,4-dione化学式
CAS
302917-36-8
化学式
C15H21N5O10
mdl
——
分子量
431.359
InChiKey
IRYGXHVZNUJTRR-SJKWGPLLSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -3.71
  • 重原子数:
    30.0
  • 可旋转键数:
    7.0
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.73
  • 拓扑面积:
    232.46
  • 氢给体数:
    6.0
  • 氢受体数:
    12.0

反应信息

  • 作为反应物:
    描述:
    1-{(2R,3R,4S,5S)-5-[(S)-1-((2S,3R,4S,5R)-5-Azidomethyl-3,4-dihydroxy-tetrahydro-furan-2-yloxy)-2-hydroxy-ethyl]-3,4-dihydroxy-tetrahydro-furan-2-yl}-1H-pyrimidine-2,4-dione三苯基膦 作用下, 以 四氢呋喃 为溶剂, 以100%的产率得到1-{(2R,3R,4S,5S)-5-[(S)-1-((2S,3R,4S,5R)-5-Aminomethyl-3,4-dihydroxy-tetrahydro-furan-2-yloxy)-2-hydroxy-ethyl]-3,4-dihydroxy-tetrahydro-furan-2-yl}-1H-pyrimidine-2,4-dione
    参考文献:
    名称:
    Synthesis of the Nucleoside Moiety of Liposidomycins: Elucidation of the Pharmacophore of this Family of MraY Inhibitors
    摘要:
    Tunicamycins (TCMs) and liposidomycins (LPMs) are naturally occurring inhibitors of the bacterial translocase (MraY). Based on structure-activity relationship (SAR) studies, a molecular model has been proposed for their inhibitory mechanism. This study points out the importance of the nucleoside moiety of liposidomycins in the inhibition of MraY. A simplified molecule (I) based on the liposidomycin core structure has been synthesised and tested on MraY. The compound displayed a moderate inhibitory activity (IC50-50 mu M). The validation of the molecular model was then performed by synthesising higher homologues of I, containing an additional stereocentre in the 5' position (XIV and XV). In agreement with the prediction, only the (S) isomer XV showed significant activity against MraY (IC50=5 mu M). (C) 2000 Elsevier Science Ltd. All rights reserved.
    DOI:
    10.1016/s0960-894x(00)00349-8
  • 作为产物:
    参考文献:
    名称:
    Synthesis of the Nucleoside Moiety of Liposidomycins: Elucidation of the Pharmacophore of this Family of MraY Inhibitors
    摘要:
    Tunicamycins (TCMs) and liposidomycins (LPMs) are naturally occurring inhibitors of the bacterial translocase (MraY). Based on structure-activity relationship (SAR) studies, a molecular model has been proposed for their inhibitory mechanism. This study points out the importance of the nucleoside moiety of liposidomycins in the inhibition of MraY. A simplified molecule (I) based on the liposidomycin core structure has been synthesised and tested on MraY. The compound displayed a moderate inhibitory activity (IC50-50 mu M). The validation of the molecular model was then performed by synthesising higher homologues of I, containing an additional stereocentre in the 5' position (XIV and XV). In agreement with the prediction, only the (S) isomer XV showed significant activity against MraY (IC50=5 mu M). (C) 2000 Elsevier Science Ltd. All rights reserved.
    DOI:
    10.1016/s0960-894x(00)00349-8
点击查看最新优质反应信息